of Family Medicine and the College of Family Physicians of Canada, and is a recipient of the Curtis Hames Research Award from the Society of Teachers of Family Medicine. He is a member of the Research Committee of the World Organization of National Academies of Family Medicine and of the Guidelines International Network Advisory Board. Previously he has been a member of the board of the Society of Teachers of Family Medicine, on the editorial boards of the Journal of Family Practice and of Family Medicine (Oxford), and the coordinator of the Cochrane Primary Health Care Field.
Rachel E. Behrman, M.D., M.P.H., is the associate commissioner for clinical programs and director of the Office of Critical Path Programs of the Food and Drug Administration (FDA). In that capacity, she is responsible for developing, coordinating, and implementing policy and scientific programs aimed at innovating development and regulation of FDA-regulated products. She also oversees the Good Clinical Practice Program, which coordinates FDA policies on human subject protection and bioresearch monitoring. Dr. Behrman joined the FDA in 1989 and has held a number of positions in the Center for Drug Evaluation and Research, including medical reviewer and team leader in the Division of Antiviral Drug Products and deputy director of the Office of Medical Policy. Dr. Behrman is a board-certified internist and infectious disease subspecialist and a fellow of the American College of Physicians. She received her A.B. in mathematics from Washington University, her M.D. from Mt. Sinai School of Medicine, and her M.P.H. from the Johns Hopkins School of Hygiene and Public Health.
Jesse A. Berlin, Sc.D., received his doctorate in biostatistics from the Harvard School of Public Health in 1988. In 1989 he joined the faculty at the University of Pennsylvania, in a unit that became the Center for Clinical Epidemiology and Biostatistics, under the direction of Dr. Brian Strom. Dr. Berlin spent several years as director of biostatistics for the University of Pennsylvania Cancer Center, followed by assuming the role of faculty director of the Biostatistics and Epidemiology Consulting Center. At the end of the summer of 2004, Dr. Berlin left Penn to join Johnson & Johnson Pharmaceutical Research and Development, where he is currently vice president of pharmaco-epidemiology. He has authored or coauthored over 220 publications in a wide variety of clinical and methodological areas. Dr. Berlin has a great deal of experience in both the application of meta-analysis and the study of meta-analytic methods as applied to both randomized trials and epidemiology. He has served as a consultant on meta-analysis for the Australian government, and has served on two Institute of Medicine (IOM)